Skip to content
  
  

Zxcoachoutlet

Business

Menu
  • business
  • finance
  • insurance
  • money
  • personal

Tag: Gilead

If You Invested $1,000 in Gilead Sciences’ IPO, This Is How Much Money You’d Have Now

October 11, 2020
| No Comments
| money

Gilead Sciences (NASDAQ:GILD) has been in the news lately, with President Trump receiving doses of Gilead’s experimental antiviral drug Veklury (remdesivir) earlier this month to help treat his coronavirus infection. It’s already been an up-and-down year for Gilead — in March, the stock hit a 52-week high of $85.97 on hopes that Veklury, originally tested to fight Ebola, would be the big answer to ending the coronavirus pandemic.

The stock slowly came down to earth, however, hurt by a May report in the New England Journal of Medicine that said Veklury only shortened the time of hospitalization by four days in COVID-19 patients, compared to a placebo.

Earlier in October, the stock was trading at about $62 a share, which — while a long way from $85 — is more than three times what it went for after its initial public offering (IPO) in January of 1992.

Businessman holding onto a climbing arrow that shows compounding interest.

Image source: Getty

… Read More

Read More »

Posted in %1$s Tagged %1$s

Alaska Bought Up Gilead, Lilly, and Wells Fargo Stock. Here’s What It Sold.

October 10, 2020
| No Comments
| business

Text size

Alaska’s Department of Revenue materially increased investments in Gilead Sciences and Eli Lilly stock in the third quarter.


David Paul Morris/Bloomberg

Alaska’s Department of Revenue made big changes in some of its biggest holdings in U.S.-traded equities.

The state agency, which is charged with collecting and investing funds for public purposes, materially increased investments in

Gilead Sciences

(ticker: GILD) and

Eli Lilly

(LLY), two companies working on treatments for Covid-19, in the third quarter. The Department of Revenue also bought more

Wells Fargo

(WFC) stock and cut holdings in

Bank of America

(BAC). The Alaskan agency disclosed the trades, among others, in a form it filed with the Securities and Exchange Commission.

Alaska’s Department of Revenue, which managed $8.1 billion in U.S.-traded equities as of Sept. 30, didn’t respond to a request for comment on its stock transactions.

The agency bought 253,419 more Gilead shares in the third

… Read More

Read More »

Posted in %1$s Tagged %1$s

Gilead, Regeneron, Amgen: Covid Treatment Stocks Still Worth Looking At As Vaccine Nears?

October 5, 2020
| No Comments
| business

Our indicative theme on Covid-19 Treatment Stocks – which includes companies selling or developing treatments for Covid-19 –  is up by 13% year-to-date, compared to the S&P 500 which is up about 4%. While anti-viral therapeutics are quite complex to develop, companies have largely been adapting existing therapies for Covid treatments while also developing new treatment options. Now the long-term demand for Covid-19 treatments is hazy, considering that the development of a safe and effective vaccine could drastically reduce or possibly eliminate the need for treatments. However, most of the companies on the list have other established products that provide significant downside protection. Below is a bit more about these companies and how they have fared this year.

Regeneron Pharmaceuticals (REGN) recently indicated that its experimental Covid-19 treatment that involves a cocktail of two antibodies was effective in reducing viral loads and improving symptoms in non-hospitalized Covid-19 patients. The stock

… Read More

Read More »

Posted in %1$s Tagged %1$s

Buy Lam Research And Sell Short Gilead

October 4, 2020
| No Comments
| business

NYSE

Photographer: Jonathan Fickies/Bloomberg News

BLOOMBERG NEWS

The market cycles are in a bottoming phase. However, October is the most volatile month, has brought the largest one-day declines, but has usually closed on the upside. Bullish sentiment was only partially doused by the correction. This month and the quarter are likely to close out on the upside but a large short-term decline cannot be ruled out.

Here are two stock recommendations for the short term.

Lam Research is entering a cycle buy phase. The daily cycle turns up on the 6th and tops on October 15th. Seven of the last eight cycles have been profitable over the last year. The weekly cycle (87% profitable) and the monthly cycle (80% correct) are also rising. Seasonality is supportive of higher prices. The stock has risen in the month of October 64% of the time, the strongest month in any year.  

… Read More

Read More »

Posted in %1$s Tagged %1$s

Recent Posts

  • Barrett says George Floyd video was ‘very personal’ for her family
  • M1 Finance closes $45M Series C mere months after it raised its $33M Series B
  • The Wake Up for Wednesday, Oct. 14, 2020
  • Business Leaders from Finance, Technology, Retail and Hospitality Call For Civility and Patience Ahead of The 2020 Election | News
  • Personal Preparedness is a Year-Round Commitment and More Important Than Ever

Archives

  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020

Categories

  • business
  • finance
  • insurance
  • money
  • personal
January 2021
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
« Oct    

Tags

Announces Bank Big billion Business Buy Car Company Coronavirus COVID19 deal Debate demand dollar finance Financial Global Group Growth Health Home insurance Investing Investors IPO Jobs Life Market Markets million money News Oil Pandemic personal Recovery report September shares Stimulus Stock stocks Talks Top Trump

About Us

  • Advertise Here
  • Contact Us
  • Privacy Policy
  • Sitemap

Hairstyle 2020 | All Rights Reserved.

Hairstyle theme by Flythemes